Patents by Inventor Simon Charles Goodacre

Simon Charles Goodacre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11731943
    Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: August 22, 2023
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Mark Zak, Terry Kellar, Yun-Xing Cheng, Wei Li, F. Anthony Romero, Paul Gibbons, Guiling Zhao, Gregory Hamilton, Simon Charles Goodacre
  • Publication number: 20230242530
    Abstract: Compounds of Formula (I) and (II), or a stereoisomer, tautomer, solvate, prodrug or salt thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: April 7, 2023
    Publication date: August 3, 2023
    Applicant: Genentech, Inc.
    Inventors: Simon Charles GOODACRE, Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG, Limin CHENG, Rongbao HUA
  • Publication number: 20230206644
    Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: February 28, 2023
    Publication date: June 29, 2023
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, Paul GIBBONS, Yun-Xing CHENG, Simon Charles GOODACRE
  • Publication number: 20230045776
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: February 25, 2021
    Publication date: February 9, 2023
    Applicant: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
  • Publication number: 20210236473
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: February 25, 2021
    Publication date: August 5, 2021
    Applicant: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
  • Publication number: 20210179564
    Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: February 17, 2021
    Publication date: June 17, 2021
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Mark Zak, Terry Kellar, Yun-Xing Cheng, Wei Li, F. Anthony Romero, Paul Gibbons, Guiling Zhao, Gregory Hamilton, Simon Charles Goodacre
  • Patent number: 10966963
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: April 6, 2021
    Assignee: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
  • Publication number: 20200339604
    Abstract: Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: July 13, 2020
    Publication date: October 29, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, Paul GIBBONS, Yun-Xing CHENG, Simon Charles GOODACRE
  • Publication number: 20200270248
    Abstract: Compounds of Formula (I) and (II), or a stereoisomer, tautomer, solvate, prodrug or salt thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: May 8, 2020
    Publication date: August 27, 2020
    Applicant: Genentech, Inc.
    Inventors: Simon Charles GOODACRE, Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG, Limin CHENG, Rongbao HUA
  • Publication number: 20190337946
    Abstract: Triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.
    Type: Application
    Filed: July 18, 2019
    Publication date: November 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Nicholas Charles Ray, Mark Edward Zak, Yun-Xing Cheng, Wei Li
  • Publication number: 20190322661
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: June 11, 2019
    Publication date: October 24, 2019
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-wai Yuen
  • Publication number: 20190202822
    Abstract: Compounds of Formula (I) and (II), or a stereoisomer, tautomer, solvate, prodrug or salt thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: March 5, 2019
    Publication date: July 4, 2019
    Applicant: Genentech, Inc.
    Inventors: Simon Charles GOODACRE, Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG, Limin CHENG, Rongbao HUA
  • Publication number: 20190071404
    Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: November 5, 2018
    Publication date: March 7, 2019
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Mark Zak, Terry Kellar, Yun-Xing Cheng, Wei Li, F. Anthony Romero, Paul Gibbons, Guiling Zhao, Gregory Hamilton, Simon Charles Goodacre
  • Publication number: 20180327402
    Abstract: Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.
    Type: Application
    Filed: May 9, 2018
    Publication date: November 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Nicholas Charles Ray, Mark Edward Zak, Yun-Xing Cheng, Wei Li
  • Publication number: 20180305355
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: November 22, 2017
    Publication date: October 25, 2018
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-wai Yuen
  • Publication number: 20180235945
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: April 17, 2018
    Publication date: August 23, 2018
    Applicant: Genentech, Inc.
    Inventors: SHARADA LABADIE, JUN LIANG, DANIEL FRED ORTWINE, XIAOJING WANG, JASON ZBIEG, BIRONG ZHANG, SIMON CHARLES GOODACRE, NICHOLAS CHARLES RAY, JUN LI, TOMMY LAI, JIANGPENG LIAO, ZHIGUO LIU, JOHN WAI, TAO WANG
  • Patent number: 10053451
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: August 21, 2018
    Assignee: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Birong Zhang, Nicholas D. Smith, Steven P. Govek, Mehmet Kahraman, Andiliy G. Lai, Johnny Y. Nagasawa, Simon Charles Goodacre, Nicholas Charles Ray
  • Patent number: 9980947
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: May 29, 2018
    Assignee: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li
  • Publication number: 20180086757
    Abstract: Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.
    Type: Application
    Filed: August 31, 2017
    Publication date: March 29, 2018
    Applicant: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Nicholas Charles Ray, Mark Edward Zak, Yun-Xing Cheng, Wei Li
  • Patent number: 9845291
    Abstract: Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: December 19, 2017
    Assignee: Genentech, Inc.
    Inventors: Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Steven P. Govek, Mehmet Kahraman, Johnny Y. Nagasawa, Nicholas D. Smith, Simon Charles Goodacre, Nicholas Charles Ray